Lotus Pharmaceutical Co Stock | 1795.TW | TW0001795003 |

Date	Lotus Pharmaceutical Co Price
9/10/2024	278.00 undefined
9/9/2024	284.50 undefined
9/6/2024	275.50 undefined
9/5/2024	266.50 undefined
9/4/2024	274.00 undefined
9/3/2024	285.50 undefined
9/2/2024	286.50 undefined
8/30/2024	287.00 undefined
8/29/2024	282.00 undefined
8/28/2024	281.00 undefined
8/27/2024	285.00 undefined
8/26/2024	281.00 undefined
8/23/2024	281.50 undefined
8/22/2024	280.00 undefined
8/21/2024	281.50 undefined
8/20/2024	284.50 undefined
8/19/2024	278.50 undefined
8/16/2024	275.00 undefined
8/15/2024	273.00 undefined
8/14/2024	272.00 undefined
8/13/2024	272.00 undefined

Date	Lotus Pharmaceutical Co Revenue	Lotus Pharmaceutical Co EBIT	Lotus Pharmaceutical Co Net Income
2026e	20.01 B undefined	11.62 B undefined	11.44 B undefined
2025e	22.24 B undefined	8.5 B undefined	6.42 B undefined
2024e	18.95 B undefined	6.21 B undefined	4.97 B undefined
2023	16.96 B undefined	4.9 B undefined	4.11 B undefined
2022	14.63 B undefined	4.11 B undefined	3.02 B undefined
2021	12.65 B undefined	2.3 B undefined	1.4 B undefined
2020	10.73 B undefined	1.61 B undefined	1.03 B undefined
2019	9.61 B undefined	1.2 B undefined	662.81 M undefined
2018	6.43 B undefined	448.69 M undefined	99.48 M undefined
2017	6.42 B undefined	547.94 M undefined	21.79 M undefined
2016	5.9 B undefined	244.38 M undefined	-134.04 M undefined
2015	5.52 B undefined	448.84 M undefined	103.95 M undefined
2014	2.31 B undefined	-443.23 M undefined	-442.13 M undefined
2013	658.5 M undefined	-25.3 M undefined	11.9 M undefined
2012	503.2 M undefined	-203.5 M undefined	-193.2 M undefined
2011	532.2 M undefined	-145.9 M undefined	-38.4 M undefined
2010	590.2 M undefined	22.8 M undefined	15.1 M undefined
2009	606.8 M undefined	40.4 M undefined	3.1 M undefined
2008	552 M undefined	33.2 M undefined	40.2 M undefined
2007	579.4 M undefined	29.2 M undefined	47.9 M undefined
2006	532.2 M undefined	31.3 M undefined	42.7 M undefined
2005	540.1 M undefined	23.2 M undefined	46.1 M undefined
2004	523.5 M undefined	38 M undefined	39.1 M undefined

	Revenue	EBIT	Net Income
2004	523.5 M TWD	38 M TWD	39.1 M TWD
2005	540.1 M TWD	23.2 M TWD	46.1 M TWD
2006	532.2 M TWD	31.3 M TWD	42.7 M TWD
2007	579.4 M TWD	29.2 M TWD	47.9 M TWD
2008	552 M TWD	33.2 M TWD	40.2 M TWD
2009	606.8 M TWD	40.4 M TWD	3.1 M TWD
2010	590.2 M TWD	22.8 M TWD	15.1 M TWD
2011	532.2 M TWD	-145.9 M TWD	-38.4 M TWD
2012	503.2 M TWD	-203.5 M TWD	-193.2 M TWD
2013	658.5 M TWD	-25.3 M TWD	11.9 M TWD
2014	2.31 B TWD	-443.23 M TWD	-442.13 M TWD
2015	5.52 B TWD	448.84 M TWD	103.95 M TWD
2016	5.9 B TWD	244.38 M TWD	-134.04 M TWD
2017	6.42 B TWD	547.94 M TWD	21.79 M TWD
2018	6.43 B TWD	448.69 M TWD	99.48 M TWD
2019	9.61 B TWD	1.2 B TWD	662.81 M TWD
2020	10.73 B TWD	1.61 B TWD	1.03 B TWD
2021	12.65 B TWD	2.3 B TWD	1.4 B TWD
2022	14.63 B TWD	4.11 B TWD	3.02 B TWD
2023	16.96 B TWD	4.9 B TWD	4.11 B TWD
2024e	18.95 B TWD	6.21 B TWD	4.97 B TWD
2025e	22.24 B TWD	8.5 B TWD	6.42 B TWD
2026e	20.01 B TWD	11.62 B TWD	11.44 B TWD

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
50	39	46	42	47	40	3	15	-38	-193	22	-586	304	19	235	163	977	0	0	0
10	11	11	14	23	24	24	27	43	62	67	163	296	306	360	391	592	709	759	936
-17	0	-8	-4	-22	-1	17	17	4	-15	0	0	0	0	0	0	0	0	0	0
-39	-8	-49	27	-1	-31	38	-12	-37	45	-198	-799	24	-20	-534	-316	-1,712	-779	-3,316	-1,642
15	9	6	1	18	8	5	12	-49	46	13	184	452	927	528	558	563	713	806	484
0	0	0	1	2	2	1	0	0	4	2	22	235	244	345	182	282	393	227	290
14	5	18	0	4	12	5	3	4	0	0	121	97	-26	295	178	110	89	259	444
0.02	0.05	0.01	0.08	0.07	0.04	0.09	0.06	-0.08	-0.05	-0.1	-1.04	1.08	1.23	0.59	0.8	0.42	1.95	0.12	3.72
-50	-15	-62	-91	-20	-11	-26	-148	-187	-80	-33	-222	-520	-660	-913	-399	-1,105	-1,997	-1,615	-3,069
-71	-4	-55	-89	-43	-9	-29	-143	-189	-106	-13	-4,723	-191	-577	-907	-498	-2,388	-1,124	-1,576	-4,656
-20	10	7	1	-23	1	-3	5	-1	-25	20	-4,500	329	83	6	-99	-1,282	872	38	-1,586
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.01	-0.02	0.05	0.03	-0.01	0.02	-0.06	0.35	0	-0.08	0.25	2.53	0.42	-0.01	0.29	-2.83	2.75	1.88	-0.16	2.33
0.09	0	0	0	0	0	0.05	0.1	0	0.23	0	0	-0.02	0	0	0	0.62	0	1.36	0
0.07	-0.04	0.03	0.01	-0.04	-0.01	-0.02	0.44	-0.01	0.16	0.93	5.53	-0.38	-0.15	0.02	-0.96	2.22	-0.55	1.66	1.26
-0.01	-0	-0	-0	-0	-0	0	0	0	0	0.68	3.01	-0.78	-0.14	-0.27	1.88	-1.15	-2.43	0.56	-0.56
-22	-15	-20	-21	-27	-27	-6	-4	-13	0	0	0	0	0	0	0	0	0	-92	-506
17	2	-23	-2	-13	20	43	359	-277	-1	819	-233	482	437	-241	-750	218	212	116	377
-31.3	36.3	-55.6	-9.8	45.1	29.1	63.4	-89.4	-264.2	-135.4	-129.3	-1,261.4	556.86	572.52	-322.56	397.91	-685.58	-48.86	-1,496.09	650.03
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Lotus Pharmaceutical Co Gross margin	Lotus Pharmaceutical Co Profit margin	Lotus Pharmaceutical Co EBIT margin	Lotus Pharmaceutical Co Profit margin
2026e	55.34 %	58.07 %	57.19 %
2025e	55.34 %	38.21 %	28.85 %
2024e	55.34 %	32.76 %	26.22 %
2023	55.34 %	28.91 %	24.21 %
2022	53.35 %	28.1 %	20.64 %
2021	44.59 %	18.15 %	11.09 %
2020	42.84 %	15.03 %	9.57 %
2019	46.01 %	12.49 %	6.9 %
2018	48.83 %	6.98 %	1.55 %
2017	47.94 %	8.53 %	0.34 %
2016	56.38 %	4.14 %	-2.27 %
2015	58.47 %	8.13 %	1.88 %
2014	49.99 %	-19.19 %	-19.14 %
2013	62.13 %	-3.84 %	1.81 %
2012	54.63 %	-40.44 %	-38.39 %
2011	61.54 %	-27.41 %	-7.22 %
2010	60.06 %	3.86 %	2.56 %
2009	59.06 %	6.66 %	0.51 %
2008	64.26 %	6.01 %	7.28 %
2007	66.67 %	5.04 %	8.27 %
2006	69.22 %	5.88 %	8.02 %
2005	69.86 %	4.3 %	8.54 %
2004	69.42 %	7.26 %	7.47 %

	Gross margin	EBIT margin	Profit margin
2004	69.42 %	7.26 %	7.47 %
2005	69.86 %	4.3 %	8.54 %
2006	69.22 %	5.88 %	8.02 %
2007	66.67 %	5.04 %	8.27 %
2008	64.26 %	6.01 %	7.28 %
2009	59.06 %	6.66 %	0.51 %
2010	60.06 %	3.86 %	2.56 %
2011	61.54 %	-27.41 %	-7.22 %
2012	54.63 %	-40.44 %	-38.39 %
2013	62.13 %	-3.84 %	1.81 %
2014	49.99 %	-19.19 %	-19.14 %
2015	58.47 %	8.13 %	1.88 %
2016	56.38 %	4.14 %	-2.27 %
2017	47.94 %	8.53 %	0.34 %
2018	48.83 %	6.98 %	1.55 %
2019	46.01 %	12.49 %	6.9 %
2020	42.84 %	15.03 %	9.57 %
2021	44.59 %	18.15 %	11.09 %
2022	53.35 %	28.1 %	20.64 %
2023	55.34 %	28.91 %	24.21 %
2024e	55.34 %	32.76 %	26.22 %
2025e	55.34 %	38.21 %	28.85 %
2026e	55.34 %	58.07 %	57.19 %

Date	Lotus Pharmaceutical Co Sales per Share	Lotus Pharmaceutical Co EBIT per share	Lotus Pharmaceutical Co Earnings per Share
2026e	75.49 undefined	0 undefined	43.17 undefined
2025e	83.89 undefined	0 undefined	24.2 undefined
2024e	71.49 undefined	0 undefined	18.75 undefined
2023	64.72 undefined	18.71 undefined	15.67 undefined
2022	55.92 undefined	15.71 undefined	11.54 undefined
2021	49.28 undefined	8.94 undefined	5.47 undefined
2020	44.06 undefined	6.62 undefined	4.22 undefined
2019	39.73 undefined	4.96 undefined	2.74 undefined
2018	26.99 undefined	1.88 undefined	0.42 undefined
2017	26.97 undefined	2.3 undefined	0.09 undefined
2016	24.78 undefined	1.03 undefined	-0.56 undefined
2015	23.17 undefined	1.88 undefined	0.44 undefined
2014	12.6 undefined	-2.42 undefined	-2.41 undefined
2013	10.16 undefined	-0.39 undefined	0.18 undefined
2012	10.25 undefined	-4.14 undefined	-3.93 undefined
2011	10.69 undefined	-2.93 undefined	-0.77 undefined
2010	12.09 undefined	0.47 undefined	0.31 undefined
2009	14.45 undefined	0.96 undefined	0.07 undefined
2008	14.37 undefined	0.86 undefined	1.05 undefined
2007	15.13 undefined	0.76 undefined	1.25 undefined
2006	13.9 undefined	0.82 undefined	1.11 undefined
2005	14.1 undefined	0.61 undefined	1.2 undefined
2004	13.67 undefined	0.99 undefined	1.02 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	13.67 TWD	0.99 TWD	1.02 TWD
2005	14.1 TWD	0.61 TWD	1.2 TWD
2006	13.9 TWD	0.82 TWD	1.11 TWD
2007	15.13 TWD	0.76 TWD	1.25 TWD
2008	14.37 TWD	0.86 TWD	1.05 TWD
2009	14.45 TWD	0.96 TWD	0.07 TWD
2010	12.09 TWD	0.47 TWD	0.31 TWD
2011	10.69 TWD	-2.93 TWD	-0.77 TWD
2012	10.25 TWD	-4.14 TWD	-3.93 TWD
2013	10.16 TWD	-0.39 TWD	0.18 TWD
2014	12.6 TWD	-2.42 TWD	-2.41 TWD
2015	23.17 TWD	1.88 TWD	0.44 TWD
2016	24.78 TWD	1.03 TWD	-0.56 TWD
2017	26.97 TWD	2.3 TWD	0.09 TWD
2018	26.99 TWD	1.88 TWD	0.42 TWD
2019	39.73 TWD	4.96 TWD	2.74 TWD
2020	44.06 TWD	6.62 TWD	4.22 TWD
2021	49.28 TWD	8.94 TWD	5.47 TWD
2022	55.92 TWD	15.71 TWD	11.54 TWD
2023	64.72 TWD	18.71 TWD	15.67 TWD
2024e	71.49 TWD	0 TWD	18.75 TWD
2025e	83.89 TWD	0 TWD	24.2 TWD
2026e	75.49 TWD	0 TWD	43.17 TWD

	Number of stocks
2004	38.3 M Aktien
2005	38.3 M Aktien
2006	38.3 M Aktien
2007	38.3 M Aktien
2008	38.4 M Aktien
2009	42 M Aktien
2010	48.8 M Aktien
2011	49.8 M Aktien
2012	49.1 M Aktien
2013	64.8 M Aktien
2014	183.36 M Aktien
2015	238.32 M Aktien
2016	238.2 M Aktien
2017	238.2 M Aktien
2018	238.2 M Aktien
2019	241.9 M Aktien
2020	243.47 M Aktien
2021	256.69 M Aktien
2022	261.68 M Aktien
2023	262.02 M Aktien
2024e	262.02 M Aktien
2025e	262.02 M Aktien
2026e	262.02 M Aktien

Date	Lotus Pharmaceutical Co Dividend
2026e	4.12 undefined
2025e	4.11 undefined
2024e	4.13 undefined
2023	3.46 undefined
2022	1.93 undefined
2021	0.35 undefined
2011	0.27 undefined
2010	0.08 undefined
2009	0.18 undefined
2008	0.82 undefined
2007	0.82 undefined
2006	0.65 undefined
2005	0.65 undefined

	Dividend	Dividend (Estimate)
2004	0 TWD	0 TWD
2005	0.65 TWD	0 TWD
2006	0.65 TWD	0 TWD
2007	0.82 TWD	0 TWD
2008	0.82 TWD	0 TWD
2009	0.18 TWD	0 TWD
2010	0.08 TWD	0 TWD
2011	0.27 TWD	0 TWD
2012	0 TWD	0 TWD
2013	0 TWD	0 TWD
2014	0 TWD	0 TWD
2015	0 TWD	0 TWD
2016	0 TWD	0 TWD
2017	0 TWD	0 TWD
2018	0 TWD	0 TWD
2019	0 TWD	0 TWD
2020	0 TWD	0 TWD
2021	0.35 TWD	0 TWD
2022	1.93 TWD	0 TWD
2023	3.46 TWD	0 TWD
2024e	0 TWD	4.13 TWD
2025e	0 TWD	4.11 TWD
2026e	0 TWD	4.12 TWD

Date	Lotus Pharmaceutical Co Payout ratio
2026e	12.14 %
2025e	13.29 %
2024e	11.57 %
2023	11.57 %
2022	16.73 %
2021	6.4 %
2020	11.57 %
2019	11.57 %
2018	11.57 %
2017	11.59 %
2016	11.63 %
2015	11.76 %
2014	12.15 %
2013	13.31 %
2012	16.8 %
2011	-34.9 %
2010	27.26 %
2009	251.86 %
2008	77.79 %
2007	65.34 %
2006	58.86 %
2005	54.45 %
2004	16.8 %

	Payout ratio
2004	16.8 %
2005	54.45 %
2006	58.86 %
2007	65.34 %
2008	77.79 %
2009	251.86 %
2010	27.26 %
2011	-34.9 %
2012	16.8 %
2013	13.31 %
2014	12.15 %
2015	11.76 %
2016	11.63 %
2017	11.59 %
2018	11.57 %
2019	11.57 %
2020	11.57 %
2021	6.4 %
2022	16.73 %
2023	11.57 %
2024e	11.57 %
2025e	13.29 %
2026e	12.14 %

Date	EPS Estimate	EPS Actual	Quarterly report
6/30/2024	5.57	5.06 (-9.23 %)	2024 Q2
3/31/2024	3.88	3.94 (1.61 %)	2024 Q1
12/31/2023	1.45	1.51 (3.84 %)	2023 Q4
9/30/2023	4.75	4.75 (-0.01 %)	2023 Q3
6/30/2023	4.31	4.84 (12.22 %)	2023 Q2
3/31/2023	3.43	4.55 (32.68 %)	2023 Q1
12/31/2022	1.19	0.63 (-47.08 %)	2022 Q4
9/30/2022	5.66	7.93 (40.21 %)	2022 Q3
6/30/2022	1.37	1.25 (-8.9 %)	2022 Q2
3/31/2022	1.51	1.71 (13.06 %)	2022 Q1
12/31/2021	1.19	0.96 (-19.18 %)	2021 Q4
9/30/2021	1.57	1.33 (-15.42 %)	2021 Q3
6/30/2021	1.83	1.38 (-24.47 %)	2021 Q2
3/31/2021	1.13	1.85 (63.57 %)	2021 Q1
12/31/2020	1.22	1.31 (6.96 %)	2020 Q4
9/30/2020	1.24	1.15 (-7.09 %)	2020 Q3
6/30/2020	1.21	1.23 (1.25 %)	2020 Q2
3/31/2020	0.75	0.54 (-27.89 %)	2020 Q1
12/31/2019	1.65	0.57 (-65.4 %)	2019 Q4
9/30/2019	1.16	0.82 (-29.48 %)	2019 Q3
6/30/2019	0.47	0.2 (-57.37 %)	2019 Q2
3/31/2019	1.74	1.16 (-33.49 %)	2019 Q1
12/31/2018	0.24	0.31 (27.94 %)	2018 Q4
9/30/2018	0.24	0.28 (14.38 %)	2018 Q3
6/30/2018	0.23	-0.23 (-198.04 %)	2018 Q2
3/31/2018	0.1	0.07 (-27.76 %)	2018 Q1
12/31/2017	0.48	-0.02 (-104.13 %)	2017 Q4
6/30/2017	0.38	0.15 (-60.25 %)	2017 Q2
3/31/2017	0.38	-0.3 (-179.49 %)	2017 Q1
3/31/2014	-0.12	-0.69 (-463.73 %)	2014 Q1
12/31/2013	-0.12	-0.27 (-120.59 %)	2013 Q4
9/30/2013	-0.37	0.08 (121.79 %)	2013 Q3
6/30/2013	-0.15	-0.11 (26.49 %)	2013 Q2

%	Name	Stocks	Change	Date
6.60884 %	Innobic LL Holding Co Ltd	17,517,000	0	12/31/2023
41.11200 %	Alvogen Emerging Markets Holdings Ltd.	108,969,000	0	12/31/2023
1.85358 %	Fuji Pharma Co Ltd	4,913,000	0	12/31/2023
1.58873 %	Uni-President Assets Management Corp.	4,211,000	4,043,000	12/31/2023
1.52995 %	The Vanguard Group, Inc.	4,055,189	-34,000	3/31/2024
0.85356 %	Norges Bank Investment Management (NBIM)	2,262,382	11,062	12/31/2023
0.75456 %	You (Zuo Chang)	2,000,000	0	12/31/2023
0.57535 %	Liao (Su Yun)	1,525,000	0	12/31/2023
0.56517 %	Capital Investment Trust Corporation	1,498,000	1,218,000	12/31/2023
0.51423 %	BlackRock Institutional Trust Company, N.A.	1,363,000	4,000	3/31/2024
0.49424 %	Lazard Asset Management Limited	1,310,000	0	2/29/2024
0.45021 %	Yuanta Securities Investment Trust Co., Ltd.	1,193,287	1,064,000	12/31/2023
0.42633 %	Vazharov (Petar)	1,130,000	0	12/31/2023
0.41991 %	Fuh Hwa Securities Investment Trust Co., Ltd.	1,113,000	366,000	12/31/2023
0.29315 %	Pzena Investment Management, LLC	777,000	127,000	6/30/2023
0.29126 %	Dimensional Fund Advisors, L.P.	772,000	0	3/31/2024
0.21467 %	Causeway Capital Management LLC	569,000	-19,000	12/31/2023
0.14801 %	BlackRock Advisors (UK) Limited	392,306	-1,000	3/31/2024
0.12260 %	SinoPac Securities Investment Trust Co., Ltd.	324,963	240	2/29/2024
0.09923 %	Robeco Institutional Asset Management B.V.	263,000	263,000	12/31/2022
0.09055 %	Union Securities Investment Trust Co., Ltd.	240,000	-80,000	12/31/2023
0.07922 %	Mega International Investment Trust Co., Ltd.	209,984	-14,974	2/29/2024
0.06942 %	Wellington Management Company, LLP	184,000	-3,000	12/31/2023
0.05621 %	Dimensional Fund Advisors, Ltd.	149,000	8,000	2/29/2024
0.05546 %	Invesco Capital Management LLC	147,000	0	3/31/2024
0.05395 %	Mellon Investments Corporation	143,000	0	3/31/2024
0.05206 %	Taishin Securities Investment Trust Co. Ltd.	138,000	138,000	12/31/2023
0.04075 %	American Century Investment Management, Inc.	108,000	0	3/31/2024
0.03924 %	Nuveen LLC	104,000	0	3/31/2024
0.03471 %	Shin Kong Investment Trust Co., Ltd.	92,000	92,000	12/31/2023
0.03433 %	KGI Securities Investment Trust Company Ltd.	91,000	91,000	12/31/2023
0.03169 %	Jih Sun Securities Investment Trust Co., Ltd.	84,000	84,000	12/31/2023
0.03018 %	CTBC Investments Co. Ltd.	80,000	80,000	12/31/2023
0.02807 %	Florida State Board of Administration	74,400	74,400	9/30/2022
0.02754 %	Victory Capital Management Inc.	73,000	-309,000	12/31/2023
0.02452 %	J O Hambro Capital Management Limited	65,000	0	9/30/2023
0.02377 %	Geode Capital Management, L.L.C.	63,000	0	2/29/2024
0.02113 %	State Street Global Advisors (US)	56,000	0	2/29/2024
0.02037 %	HSBC Global Asset Management (Taiwan) Limited	54,000	54,000	12/31/2023
0.01924 %	Janus Henderson Investors	51,000	0	9/30/2023
0.01849 %	Fuh Hwa SITE Asset Management (Hong Kong) Limited	49,000	49,000	12/31/2023
0.01660 %	Lazard Asset Management, L.L.C.	44,000	-184,000	12/31/2023
0.01547 %	State Street Global Advisors Ireland Limited	41,000	-1,000	3/31/2024
0.01547 %	Parametric Portfolio Associates LLC	41,000	0	1/31/2024
0.00943 %	AXA Investment Managers UK Ltd.	25,000	25,000	6/30/2023
0.00858 %	HSBC Global Asset Management (UK) Limited	22,747	13,380	1/31/2024
0.00717 %	Avantis Investors	19,000	0	3/31/2024
0.00566 %	Phillip Capital Management (S) Ltd.	15,000	15,000	6/30/2023
0.00566 %	Vanguard Global Advisers LLC	15,000	0	2/29/2024
0.00529 %	DFA Australia Ltd.	14,026	-101	12/31/2023
0.00415 %	First Securities Investment Trust Co., Ltd.	11,000	-85,000	12/31/2023
0.00377 %	Origin Asset Management LLP	10,000	0	2/29/2024
0.00323 %	Vanguard Investments Australia Ltd.	8,560	72	2/29/2024
0.00189 %	Degroof Petercam Asset Services SA	5,000	5,000	9/30/2023
0.00117 %	TimesSquare Capital Management, LLC	3,100	0	2/29/2024
0.00075 %	Northern Trust Investments, Inc.	2,000	0	3/31/2024
0.00074 %	Irish Life Investment Managers Ltd.	1,968	-448	2/29/2024
0.00049 %	Dorsey, Wright & Associates, LLC	1,300	1,300	5/31/2023
0.00038 %	State Street Global Advisors Australia Ltd.	1,000	0	1/31/2024
0 %	Sophus Capital	0	-340,000	12/31/2023
0 %	USAA Asset Management Company	0	-90,000	3/31/2024
0 %	RAM Active Investments S.A.	0	-22,000	6/30/2023
0 %	Taiwan Cooperative Securities Investment Trust Co., Ltd.	0	-73,000	9/30/2023
0 %	EAM Investors, LLC	0	-119,255	9/30/2023
0 %	BlackRock Advisors, LLC	0	-4,000	4/30/2023
0 %	Franklin Templeton Investments (Asia) Ltd.	0	-239,000	9/30/2022
0 %	Artico Partners AG	0	-3,000	12/31/2023
0 %	Franklin Templeton SinoAm Securities Investment Management	0	-100,000	3/31/2023
0 %	SEI Investments Management Corporation	0	-60,000	11/30/2023
0 %	Neuberger Berman, LLC	0	-152,000	3/31/2023
0 %	Nomura Asset Management Taiwan Limited	0	-832,000	9/30/2023
0 %	First Trust Advisors L.P.	0	-46,295	10/31/2022
0 %	PGIM Securities Investment Trust Enterprise	0	-100,000	12/31/2023
0 %	Eastspring Investments (Singapore) Limited	0	-106,000	11/30/2023
0 %	Hua Nan Investment Trust Corp.	0	-100,000	9/30/2023
0 %	Segall Bryant & Hamill, LLC	0	-7,000	11/30/2023
0 %	Oberweis Asset Management, Inc.	0	-50,000	6/30/2023
0 %	Fubon Asset Management Company Ltd.	0	-148,000	4/30/2023
0 %	Goldman Sachs Asset Management International	0	-54,400	11/30/2023
0 %	Harding Loevner LP	0	-81,000	12/31/2023
0 %	M&G Investment Management Ltd.	0	-254,000	2/28/2023
0 %	Schroder Investment Management Ltd. (SIM)	0	-11,000	5/31/2023
0 %	SEB Investment Management AB	0	-1,000	5/31/2023
0 %	Fidelity Management & Research Company LLC	0	-98,000	11/30/2023
0 %	Goldman Sachs Asset Management, L.P.	0	-186,000	1/31/2023
0 %	Mercer Global Investments Management Ltd	0	-285,000	12/31/2023

What values and corporate philosophy does Lotus Pharmaceutical Co represent?

Lotus Pharmaceutical Co Ltd represents a commitment to quality, innovation, and patient-centric care in the pharmaceutical industry. As a leading company, Lotus upholds a corporate philosophy focused on scientific research, integrity, and social responsibility. The company aims to improve global healthcare by providing safe, effective, and reliable pharmaceutical products. Lotus Pharmaceutical Co Ltd's dedication to technological advancements and strategic partnerships ensures the development and delivery of high-quality medicines to meet the evolving needs of patients worldwide. With a steadfast focus on customer satisfaction and a passion for advancing medical science, Lotus Pharmaceutical Co Ltd is poised to make significant contributions to the healthcare landscape.

In which countries and regions is Lotus Pharmaceutical Co primarily present?

Lotus Pharmaceutical Co Ltd is primarily present in Taiwan, with its headquarters located in Taipei. The company focuses on the research, development, production, and distribution of various pharmaceutical products. As a leading pharmaceutical company in Taiwan, Lotus Pharmaceutical Co Ltd has expanded its presence and established business relationships with international partners, extending its reach to other countries and regions, including China, Southeast Asia, and the United States. With its commitment to delivering high-quality medications and innovative healthcare solutions, Lotus Pharmaceutical Co Ltd continues to enhance its global footprint and bring its products to patients worldwide.

What significant milestones has the company Lotus Pharmaceutical Co achieved?

Lotus Pharmaceutical Co Ltd, a leading pharmaceutical company, has achieved a multitude of significant milestones. Over the years, the company has made remarkable progress in research and development, expanding its product portfolio with innovative and high-quality medicines. Lotus Pharmaceutical Co Ltd has successfully obtained various regulatory approvals for its groundbreaking drugs, enabling them to reach a wider patient population. Additionally, the company has experienced tremendous growth and has established a strong global presence, becoming a key player in the pharmaceutical industry. With a commitment to excellence and a forward-thinking approach, Lotus Pharmaceutical Co Ltd continues to set new milestones, revolutionizing healthcare solutions for a better future.

What is the history and background of the company Lotus Pharmaceutical Co?

Lotus Pharmaceutical Co Ltd is a prominent pharmaceutical company with a rich history and noteworthy background. Established in [year], Lotus Pharmaceutical has been a leading player in the pharmaceutical industry, offering a wide range of high-quality and innovative healthcare solutions. With a strong focus on research and development, Lotus Pharmaceutical has successfully introduced numerous breakthrough products that have positively impacted the medical community and patients around the world. Through its dedication to excellence and commitment to improving global healthcare, Lotus Pharmaceutical Co Ltd has earned a stellar reputation as a trusted and reliable provider within the pharmaceutical sector.

Who are the main competitors of Lotus Pharmaceutical Co in the market?

The main competitors of Lotus Pharmaceutical Co Ltd in the market include Company A, Company B, and Company C. These companies are prominent players in the pharmaceutical industry and often vie for market share in areas such as drug development, production, and distribution. Despite facing stiff competition, Lotus Pharmaceutical Co Ltd has positioned itself as a strong contender through its commitment to innovation, product quality, and customer satisfaction.

In which industries is Lotus Pharmaceutical Co primarily active?

Lotus Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry. With a focus on research, development, and manufacturing, Lotus Pharmaceutical Co Ltd operates in various sectors within the pharmaceutical industry, including generic drugs, innovative drugs, and biopharmaceuticals. As one of the leading pharmaceutical companies, Lotus Pharmaceutical Co Ltd aims to improve global healthcare by providing high-quality medicines and innovative healthcare solutions. With its extensive product portfolio and commitment to research, Lotus Pharmaceutical Co Ltd continues to play a significant role in advancing healthcare worldwide.

What is the business model of Lotus Pharmaceutical Co?

Lotus Pharmaceutical Co Ltd operates in the pharmaceutical industry, focusing on the research, development, production, and sale of a wide range of pharmaceutical products. The company's business model revolves around leveraging its expertise in drug discovery, clinical development, and manufacturing to produce high-quality and affordable medications. Lotus Pharmaceutical Co Ltd aims to address critical healthcare needs by continually expanding its product portfolio, enhancing production capabilities, and investing in research and development activities. By prioritizing innovation, quality, and accessibility, Lotus Pharmaceutical Co Ltd strives to improve global health outcomes and contribute to the growth and sustainability of the pharmaceutical industry.

What is the P/E ratio of Lotus Pharmaceutical Co 2024?

The Lotus Pharmaceutical Co P/E ratio is 14.66.

What is the P/S ratio of Lotus Pharmaceutical Co 2024?

The Lotus Pharmaceutical Co P/S ratio is 3.84.

What is the AlleAktien quality score of Lotus Pharmaceutical Co?

The AlleAktien quality score for Lotus Pharmaceutical Co is 7/10.

What is the revenue of Lotus Pharmaceutical Co 2024?

The expected Lotus Pharmaceutical Co revenue is 18.95 B TWD.

How high is the profit of Lotus Pharmaceutical Co 2024?

The expected Lotus Pharmaceutical Co profit is 4.97 B TWD.

What is the business model of Lotus Pharmaceutical Co

Lotus Pharmaceutical Co. Ltd. is a leading company in the pharmaceutical industry based in Taiwan. The company was founded in 1965 and is now a major player in the Asian pharmaceutical market. Lotus Pharmaceutical Co. Ltd. specializes in the development, production, and marketing of drugs and operates in various areas.

What is the Lotus Pharmaceutical Co dividend?

Lotus Pharmaceutical Co pays a dividend of 1.93 TWD distributed over payouts per year.

How often does Lotus Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Lotus Pharmaceutical Co or the company does not pay out a dividend.

What is the Lotus Pharmaceutical Co ISIN?

The ISIN of Lotus Pharmaceutical Co is TW0001795003.

What is the Lotus Pharmaceutical Co ticker?

The ticker of Lotus Pharmaceutical Co is 1795.TW.

How much dividend does Lotus Pharmaceutical Co pay?

Over the past 12 months, Lotus Pharmaceutical Co paid a dividend of 3.46 TWD . This corresponds to a dividend yield of about 1.24 %. For the coming 12 months, Lotus Pharmaceutical Co is expected to pay a dividend of 4.11 TWD.

What is the dividend yield of Lotus Pharmaceutical Co?

The current dividend yield of Lotus Pharmaceutical Co is 1.24 %.

When does Lotus Pharmaceutical Co pay dividends?

Lotus Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, September.

How secure is the dividend of Lotus Pharmaceutical Co?

Lotus Pharmaceutical Co paid dividends every year for the past 6 years.

What is the dividend of Lotus Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 4.11 TWD are expected. This corresponds to a dividend yield of 1.48 %.

In which sector is Lotus Pharmaceutical Co located?

Lotus Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lotus Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lotus Pharmaceutical Co from 8/30/2024 amounting to 4.647 TWD, you needed to have the stock in your portfolio before the ex-date on 8/5/2024.

When did Lotus Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/30/2024.

What was the dividend of Lotus Pharmaceutical Co in the year 2023?

In the year 2023, Lotus Pharmaceutical Co distributed 1.931 TWD as dividends.

In which currency does Lotus Pharmaceutical Co pay out the dividend?

The dividends of Lotus Pharmaceutical Co are distributed in TWD.

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0.5	0.52	0.54	0.53	0.58	0.55	0.61	0.59	0.53	0.5	0.66	2.31	5.52	5.9	6.42	6.43	9.61	10.73	12.65	14.63	16.96	18.95	22.24	20.01
-	4.81	3.25	-1.48	8.83	-4.66	9.78	-2.64	-9.83	-5.45	30.82	251.06	139.00	6.90	8.83	0.08	49.52	11.62	17.91	15.68	15.90	11.73	17.35	-10.01
70.14	69.41	69.81	69.17	66.67	64.13	59.08	60.00	61.47	54.47	62.16	49.96	58.47	56.39	47.94	48.83	46.00	42.84	44.59	53.35	55.33	-	-	-
0.35	0.36	0.38	0.37	0.39	0.35	0.36	0.35	0.33	0.27	0.41	1.15	3.23	3.33	3.08	3.14	4.42	4.6	5.64	7.81	9.38	0	0	0
0.04	0.04	0.02	0.03	0.03	0.03	0.04	0.02	-0.15	-0.2	-0.03	-0.44	0.45	0.24	0.55	0.45	1.2	1.61	2.3	4.11	4.9	6.21	8.5	11.62
7.82	7.27	4.26	5.83	5.01	5.98	6.60	3.73	-27.26	-40.36	-3.80	-19.18	8.11	4.13	8.52	6.97	12.49	15.03	18.14	28.10	28.91	32.76	38.21	58.07
0.05	0.04	0.05	0.04	0.05	0.04	0	0.02	-0.04	-0.19	0.01	-0.44	0.1	-0.13	0.02	0.1	0.66	1.03	1.4	3.02	4.11	4.97	6.42	11.44
-	-22.00	17.95	-8.70	11.90	-14.89	-92.50	400.00	-353.33	407.89	-105.70	-4,118.18	-123.30	-230.10	-115.67	371.43	568.69	54.98	36.74	115.25	35.93	21.02	29.13	78.36
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30.8	38.3	38.3	38.3	38.3	38.4	42	48.8	49.8	49.1	64.8	183.36	238.32	238.2	238.2	238.2	241.9	243.47	256.69	261.68	262.02	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0.1	0.09	0.06	0.06	0.05	0.07	0.11	0.47	0.26	0.24	1.17	0	0	2.04	1.77	1.02	1.28	1.49	1.61	1.98	1.77
0.12	0.11	0.11	0.12	0.13	0.12	0.13	0.15	0.14	0.11	1.81	0	0	1.19	1.24	1.13	2.24	2.74	3.26	4.65	6.38
26	34	44	42	31	31	22	22	28	5	634.93	0	0	190.35	165.33	83.84	174.51	64.93	150.3	276.24	233.13
0.06	0.07	0.08	0.06	0.07	0.08	0.09	0.07	0.11	0.11	1.03	0	0	0.97	0.92	1.16	1.34	2.21	3.07	3.33	3.78
37	13	26	25	36	32	36	23	39	32	202.32	0	0	80.08	99.81	161.97	684.14	284.61	247.24	420.4	489.37
0.34	0.31	0.32	0.3	0.31	0.33	0.39	0.73	0.58	0.5	4.85	0	0	4.47	4.21	3.56	5.72	6.78	8.33	10.66	12.65
0.11	0.11	0.16	0.24	0.23	0.22	0.24	0.34	0.49	0.51	1.99	0	0	1.95	1.89	1.81	2.05	2.31	2.64	3.15	3.51
0.02	0.01	0.01	0.01	0.05	0.04	0.04	0.04	0.03	0.02	0.05	0	0	0.02	0.01	0.01	0.46	0.41	0.3	2.16	3.05
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	152.6
0	0	0	0	0	0	0	0	0.01	0.01	1.78	0	0	1.88	2.38	2.19	2.91	3.83	3.86	7.32	7.36
0	0	0	0	0	0	0	0	0	0	6.29	0	0	6.01	6.13	6.08	5.91	5.9	5.59	5.67	5.67
0.01	0.03	0.04	0.04	0.06	0.05	0.04	0.02	0.02	0.06	1.39	0	0	0.91	1.02	1.2	1.15	0.53	0.5	0.58	0.59
0.14	0.16	0.21	0.29	0.34	0.31	0.32	0.41	0.54	0.59	11.51	0	0	10.78	11.43	11.29	12.47	12.97	12.89	18.86	20.34
0.47	0.46	0.53	0.58	0.65	0.65	0.71	1.14	1.12	1.09	16.35	0	0	15.24	15.64	14.85	18.19	19.75	21.22	29.53	32.99

0.22	0.26	0.27	0.27	0.27	0.3	0.36	0.43	0.45	0.57	2.38	0	0	2.38	2.38	2.38	2.43	2.45	2.63	2.63	2.65
0.04	0.02	0.03	0.02	0.02	0.02	0.03	0.15	0.15	0.26	6.15	0	0	6.15	6.02	6.02	6.59	6.8	8.04	7.53	7.13
0.06	0.05	0.06	0.08	0.1	0.08	0.06	0.05	-0	-0.2	-0.67	0	0	-0.8	-1.03	-1	-0.65	0.35	1.7	4.82	8.9
0	0	0	0	0	1	1	13	1	1	31.29	0	0	-283.32	-108.79	-181.74	-453.77	-658.47	-971.97	-786.49	-1,213.52
0	0	0	5	5	5	5	5	5	5	0	0	0	0	-1	0	-170.45	-202.51	-268.98	-271.94	-81.97
0.32	0.33	0.36	0.38	0.4	0.41	0.46	0.65	0.6	0.64	7.9	0	0	7.46	7.27	7.23	7.74	8.75	11.13	13.93	17.38
0.04	0.04	0.06	0.04	0.05	0.04	0.07	0.05	0.05	0.04	0.46	0	0	0.47	0.42	0.73	0.93	1.73	0.75	1.4	0.67
47	43	36	32	37	38	56	59	73	69	0	0	0	0	0	0	0	0	0.93	0.96	0
0.03	0.03	0.01	0.03	0.04	0.03	0.05	0.04	0.05	0.06	1.95	0	0	1.02	1.02	0.77	1.07	1.34	1.9	4.22	1.97
27	3	50	25	10	45	21	0	0	65	486.55	0	0	360	260	310	460	410	819.77	155.92	510
0	0	0	0.02	0.02	0.02	0.01	0	0.32	0.14	0.09	0	0	1.38	0.2	0.3	0.64	1.4	0.86	0.12	1.37
0.13	0.11	0.15	0.15	0.16	0.17	0.21	0.15	0.49	0.37	2.98	0	0	3.24	1.9	2.1	3.1	4.88	4.33	5.89	4.52
0	0	0	0.04	0.05	0.03	0.01	0.31	0	0.05	3.61	0	0	2.71	4.41	1.46	3.84	5.02	4.71	8.64	9.7
0	0	0	0	0	0	0	0	0	0	423.95	0	0	252.49	244.63	197.21	172.25	144.69	304.15	448.4	721.2
0.02	0.02	0.02	0.02	0.05	0.04	0.04	0.03	0.03	0.03	0.53	0	0	0.68	1.43	3.41	3.36	0.96	0.81	0.67	0.71
0.02	0.02	0.02	0.06	0.1	0.07	0.05	0.34	0.03	0.08	4.57	0	0	3.65	6.08	5.07	7.38	6.12	5.83	9.77	11.13
0.16	0.13	0.17	0.2	0.26	0.24	0.25	0.49	0.52	0.45	7.55	0	0	6.88	7.98	7.17	10.48	11.01	10.15	15.66	15.66
0.47	0.46	0.53	0.58	0.65	0.65	0.71	1.14	1.12	1.09	15.45	0	0	14.34	15.25	14.4	18.22	19.75	21.28	29.58	33.04

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

Ticker1795.TW

ISINTW0001795003

Lotus Pharmaceutical Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Lotus Pharmaceutical Co Stock Price History

Lotus Pharmaceutical Co Revenue, EBIT, Net Income TW0001795003 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Lotus Pharmaceutical Co Revenue, EBIT and net profit per share

Lotus Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Lotus Pharmaceutical Co stock margins TW0001795003 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Lotus Pharmaceutical Co Margin History

Lotus Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share TW0001795003 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Lotus Pharmaceutical Co Revenue, EBIT and net profit per share

Lotus Pharmaceutical Co business model

Lotus Pharmaceutical Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Lotus Pharmaceutical Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Lotus Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Lotus Pharmaceutical Co shares outstanding TW0001795003 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Lotus Pharmaceutical Co Stock splits

Lotus Pharmaceutical Co dividend history and estimates TW0001795003 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Lotus Pharmaceutical Co Dividend History

Lotus Pharmaceutical Co dividend payout ratio TW0001795003 ·

Payout ratio

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
1795.TW

ISIN
TW0001795003